These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 24919951)

  • 21. Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells.
    Filipović A; Lombardo Y; Faronato M; Abrahams J; Aboagye E; Nguyen QD; d'Aqua BB; Ridley A; Green A; Rahka E; Ellis I; Recchi C; Przulj N; Sarajlić A; Alattia JR; Fraering P; Deonarain M; Coombes RC
    Breast Cancer Res Treat; 2014 Nov; 148(2):455-62. PubMed ID: 25248409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
    Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.
    D'Assoro AB; Liu T; Quatraro C; Amato A; Opyrchal M; Leontovich A; Ikeda Y; Ohmine S; Lingle W; Suman V; Ecsedy J; Iankov I; Di Leonardo A; Ayers-Inglers J; Degnim A; Billadeau D; McCubrey J; Ingle J; Salisbury JL; Galanis E
    Oncogene; 2014 Jan; 33(5):599-610. PubMed ID: 23334326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
    Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
    Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells.
    Kim MR; Choi HK; Cho KB; Kim HS; Kang KW
    Cancer Sci; 2009 Oct; 100(10):1834-41. PubMed ID: 19681904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VAV3 mediates resistance to breast cancer endocrine therapy.
    Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
    Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
    McClements L; Annett S; Yakkundi A; O'Rourke M; Valentine A; Moustafa N; Alqudah A; Simões BM; Furlong F; Short A; McIntosh SA; McCarthy HO; Clarke RB; Robson T
    BMC Cancer; 2019 Apr; 19(1):351. PubMed ID: 30975104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
    Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
    Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor.
    Harrison H; Farnie G; Howell SJ; Rock RE; Stylianou S; Brennan KR; Bundred NJ; Clarke RB
    Cancer Res; 2010 Jan; 70(2):709-18. PubMed ID: 20068161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Function of Integrin-Linked Kinase in Modulating the Stemness of IL-6-Abundant Breast Cancer Cells by Regulating γ-Secretase-Mediated Notch1 Activation in Caveolae.
    Hsu EC; Kulp SK; Huang HL; Tu HJ; Salunke SB; Sullivan NJ; Sun D; Wicha MS; Shapiro CL; Chen CS
    Neoplasia; 2015 Jun; 17(6):497-508. PubMed ID: 26152358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties.
    Liu H; Zhang HW; Sun XF; Guo XH; He YN; Cui SD; Fan QX
    Chin Med J (Engl); 2013 Aug; 126(16):3030-4. PubMed ID: 23981606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Notch4+ cancer stem-like cells promote the metastatic and invasive ability of melanoma.
    Lin X; Sun B; Zhu D; Zhao X; Sun R; Zhang Y; Zhang D; Dong X; Gu Q; Li Y; Liu F
    Cancer Sci; 2016 Aug; 107(8):1079-91. PubMed ID: 27234159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Curcumin attenuates lncRNA H19‑induced epithelial‑mesenchymal transition in tamoxifen‑resistant breast cancer cells.
    Cai J; Sun H; Zheng B; Xie M; Xu C; Zhang G; Huang X; Zhuang J
    Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33179087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer.
    Ward A; Balwierz A; Zhang JD; Küblbeck M; Pawitan Y; Hielscher T; Wiemann S; Sahin Ö
    Oncogene; 2013 Feb; 32(9):1173-82. PubMed ID: 22508479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Notch Signaling in Breast Cancer: A Role in Drug Resistance.
    BeLow M; Osipo C
    Cells; 2020 Sep; 9(10):. PubMed ID: 33003540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.
    Petri BJ; Piell KM; South Whitt GC; Wilt AE; Poulton CC; Lehman NL; Clem BF; Nystoriak MA; Wysoczynski M; Klinge CM
    Cancer Lett; 2021 Oct; 518():152-168. PubMed ID: 34273466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators.
    Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A
    Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner.
    Shao S; Zhao X; Zhang X; Luo M; Zuo X; Huang S; Wang Y; Gu S; Zhao X
    Mol Cancer; 2015 Feb; 14(1):28. PubMed ID: 25645291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sorcin silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo.
    Hu Y; Li S; Yang M; Yan C; Fan D; Zhou Y; Zhang Y; Yagüe E; Xiong D
    Breast Cancer Res Treat; 2014 Jan; 143(2):287-99. PubMed ID: 24337682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.